Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-12-13
2011-10-04
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S236000
Reexamination Certificate
active
08030306
ABSTRACT:
The present application describes CB-1 inverse agonists according to Formula (I) and (Ia), pharmaceutical compositions comprising at least one compound according to Formula (I) or (Ia), and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula (I) or (Ia), both alone and in combination with one or more additional therapeutic agents. The preferred compounds have the general Formula (Ia), including all prodrugs, pharmaceutically acceptable salts and stereoisomer, thereof, wherein R1, R2, Ar1, Ar2are defined herein.
REFERENCES:
patent: 7629342 (2009-12-01), Ewing et al.
patent: 7777036 (2010-08-01), Kamboj et al.
patent: 2005/0171110 (2005-08-01), Yu et al.
patent: 2010/0216848 (2010-08-01), Peresypkin et al.
patent: WO 2005/063762 (2005-07-01), None
patent: WO 2005063762 (2005-07-01), None
patent: WO 2006/138682 (2006-12-01), None
Ewing William R.
Sulsky Richard B.
Zhu Yeheng
Bristol--Myers Squibb Company
Jaisle Cecilia M
Wang Ying
Wilson James O
LandOfFree
Azabicyclic heterocycles as cannabinoid receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azabicyclic heterocycles as cannabinoid receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azabicyclic heterocycles as cannabinoid receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4268635